JP2018521969A5 - - Google Patents

Download PDF

Info

Publication number
JP2018521969A5
JP2018521969A5 JP2017560131A JP2017560131A JP2018521969A5 JP 2018521969 A5 JP2018521969 A5 JP 2018521969A5 JP 2017560131 A JP2017560131 A JP 2017560131A JP 2017560131 A JP2017560131 A JP 2017560131A JP 2018521969 A5 JP2018521969 A5 JP 2018521969A5
Authority
JP
Japan
Prior art keywords
virus
cancer
pharmaceutical composition
crystal
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017560131A
Other languages
English (en)
Japanese (ja)
Other versions
JP6851989B2 (ja
JP2018521969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/032856 external-priority patent/WO2016187191A1/en
Publication of JP2018521969A publication Critical patent/JP2018521969A/ja
Publication of JP2018521969A5 publication Critical patent/JP2018521969A5/ja
Application granted granted Critical
Publication of JP6851989B2 publication Critical patent/JP6851989B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017560131A 2015-05-18 2016-05-17 医薬用共結晶及びその用途 Expired - Fee Related JP6851989B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163256P 2015-05-18 2015-05-18
US62/163,256 2015-05-18
PCT/US2016/032856 WO2016187191A1 (en) 2015-05-18 2016-05-17 A pharmaceutical co-crystal and use thereof

Publications (3)

Publication Number Publication Date
JP2018521969A JP2018521969A (ja) 2018-08-09
JP2018521969A5 true JP2018521969A5 (enExample) 2019-06-13
JP6851989B2 JP6851989B2 (ja) 2021-03-31

Family

ID=57320544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560131A Expired - Fee Related JP6851989B2 (ja) 2015-05-18 2016-05-17 医薬用共結晶及びその用途

Country Status (9)

Country Link
US (1) US10751318B2 (enExample)
EP (1) EP3297624B1 (enExample)
JP (1) JP6851989B2 (enExample)
KR (1) KR20180008594A (enExample)
CN (1) CN108135877B (enExample)
AU (1) AU2016265922B2 (enExample)
BR (1) BR112017024727A2 (enExample)
CA (1) CA2986136A1 (enExample)
WO (1) WO2016187191A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135877B (zh) 2015-05-18 2021-04-13 新纳特产品公司 药物共晶及其用途
JP6768716B2 (ja) 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途
CN109053808B (zh) * 2017-06-21 2020-12-29 宋勤华 一种高纯度双环铂针状晶体的工业化制备方法
KR102783770B1 (ko) * 2017-11-21 2025-03-18 메돈케어 파마수티컬 씨오., 엘티디 디시클로플라틴을 함유하는 복합 산물, 이의 제조 및 용도
CN116217628B (zh) * 2023-05-08 2023-07-14 华东理工常熟研究院有限公司 奥沙利铂Pt(IV)配合物的共晶及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3290365A (en) * 1963-06-21 1966-12-06 Standard Oil Co Method of preparing cis-cyclobutane-1, 2-dicarboxylic acid
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
KR100317473B1 (ko) 1999-05-11 2001-12-22 이계호 신규의 백금(iv)착제 및 그 제조방법
CN1121380C (zh) * 2000-03-03 2003-09-17 北京兴大豪斯科技有限公司 一种抗肿瘤的双二羧酸二氨络铂衍生物及其药物组合物
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
WO2003045962A1 (fr) * 2001-11-30 2003-06-05 Jingzun Wang Derives de carboplatine supramoleculaires, leur preparation, compositions pharmaceutiques les contenant comme ingredient actif et utilisations de ces compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
BR0313593A (pt) 2002-08-19 2005-07-12 Pfizer Prod Inc Terapia de combinação para doenças hiperproliferativas
WO2004099224A1 (de) 2003-05-05 2004-11-18 Universität Regensburg Carboplatin-artige platin (ii)- komplexe
MX2007008810A (es) 2005-01-21 2007-11-21 Astex Therapeutics Ltd Compuestos farmaceuticos.
RU2008135369A (ru) * 2006-01-30 2010-03-10 Платко Текнолоджис (Проприэтэри) Лимитед (Za) Получение комплексов платины(ii)
PL2049109T3 (pl) 2006-08-02 2016-05-31 Sunesis Pharmaceuticals Inc Skojarzone zastosowanie kwasu (+)-1,4-dihydro-7-[(3s,4s)-3-metoksy-4-(metyloamino)-1-pirolidynylo]-4-okso-1-(2-tiazolilo)-1,8-naftyrydyno-3-karboksylowego i cytarabiny (Ara-C) do leczenia białaczki
AU2009290365B2 (en) 2008-09-15 2014-08-14 Kasina Laila Innova Pharmaceuticals Private Limited Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CZ302618B6 (cs) * 2009-09-10 2011-08-03 Univerzita Palackého Cyklobutan-1,1-dikarboxylátokomplexy platiny s deriváty N6-benzyladeninu, zpusoby jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
US20110287110A1 (en) 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
SI3424920T1 (sl) 2013-10-17 2020-08-31 Vertex Pharmaceuticals Incorporated Kokristali (s)-n-metil-8-(1-((2'-metil-(4,5'-bipirimidin)-6-il)amino)propan-2-il) kinolin-4-karboksamida in devterirani derivati le-teh kot inhibitorji dna-pk
US20180085377A1 (en) 2015-04-22 2018-03-29 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
CN108135877B (zh) 2015-05-18 2021-04-13 新纳特产品公司 药物共晶及其用途
JP6768716B2 (ja) * 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー カルボプラチンベースの共結晶の医薬組成物及びその用途
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CN107847521A (zh) 2015-06-25 2018-03-27 新纳特产品公司 药物共晶组合物及其用途

Similar Documents

Publication Publication Date Title
JP2018521969A5 (enExample)
JP2018504379A5 (enExample)
JP2014503525A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2017536344A5 (enExample)
JP2013056886A5 (enExample)
JP2013545785A5 (enExample)
JP2018520147A5 (enExample)
JP2015505296A5 (enExample)
JP2014521688A5 (enExample)
JP2017504635A5 (enExample)
JP2019512478A5 (enExample)
JP2011519854A5 (enExample)
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
JP2013518107A5 (enExample)
JP2017537940A5 (enExample)
JP2020532547A5 (enExample)
JP2014507421A5 (enExample)
JP2013544804A5 (enExample)
JP2005036009A5 (enExample)
JP2013521312A5 (enExample)
JP2020507589A5 (enExample)
JP2015517555A5 (enExample)
JP2007511504A5 (enExample)
JP2013534248A5 (enExample)